Stem Memory T Cell Expansion Medium for Higher Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for ex vivo expansion of stem cell memory T cells are inefficient, resulting in low production yields and suboptimal therapeutic effects against cancer.
Innovation Solution
A composition comprising interleukin-7, interleukin-15, N-acetylcysteine, and human platelet lysate is used to culture a cell population, achieving a high proportion of CD3+CD45RO−CD197+CD95+ stem cell memory T cells, along with other T cell subsets, enhancing their cytotoxic effects against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used for ex vivo expansion of stem cell memory T cells, then the expansion process can be completed, but the production yield is low and therapeutic effects are suboptimal
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration ranges of interleukin-7 (25-50 U/mL), interleukin-15 (10-50 U/mL), N-acetylcysteine (1-10 mM), and human platelet lysate (0-10% v/v) in the culture medium. These specific parameter adjustments create optimal conditions for stem cell memory T cell expansion, achieving both high production yield and superior therapeutic effects against cancer cells.
Solution Approach 2:
The patent uses a composite culture medium containing multiple components working synergistically: interleukin-7 and interleukin-15 as growth factors, N-acetylcysteine as an antioxidant, and human platelet lysate as a supplement. This composite formulation creates a balanced microenvironment that simultaneously promotes high-level expansion and maintains the functional quality of stem cell memory T cells for effective cancer therapy.
2Productivity
If the expansion process is optimized for high yield, then production efficiency improves, but the quality and functionality of the cell population may deteriorate
Solution Approach 1:
The patent maintains manufacturing precision by carefully controlling multiple parameters simultaneously: interleukin-7 at 25-50 U/mL, interleukin-15 at 10-50 U/mL, N-acetylcysteine at 1-10 mM, and human platelet lysate at 0-10% v/v. This multi-parameter optimization ensures that high production efficiency is achieved without compromising the quality, functionality, or purity of the stem cell memory T cell population.
Solution Approach 2:
The patent ensures continuous useful action by maintaining stable culture conditions throughout the expansion process. The culture medium is designed to continuously provide growth factors, antioxidants, and supplements that support both rapid expansion and high-quality cell maintenance, preventing deterioration of cell functionality during prolonged culture periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a cell population with a high proportion of stem cell memory T cells and improved cytotoxic effects against cancer cells, suitable for cancer treatment and CAR-T therapy.
Implementation Method 1
The composition comprises 25 U/mL to 50 U/mL of interleukin-7 (IL-7) or 0.192 ng/mL to 25 ng/mL of interleukin-7; 10 U/mL to 50 U/mL of interleukin-15 (IL-15) or 0.5 ng/mL to 25 ng/mL of interleukin-15
Implementation Method 2
1 mM to 10 mM of N-acetylcysteine (NAC)
Implementation Method 3
0% to 10% (v/v) of human platelet lysate (hPL)
Data Source
AI summary
The composition and method for ex vivo expansion of stem cell memory T cells provided by the embodiments of the present disclosure can amplify and culture a cell population with a higher proportion of memory T stem cells, a higher combined proportion of memory T stem cells and central memory T cells, and a higher proportion of natural killer T cells compared to other processes. Additionally, the obtained cell population demonstrates excellent cytotoxic effects against bone cancer and pancreatic cancer cell lines, leading to the production of cell products with enhanced cell therapy efficacy.